Health Care · NYSE: TDOC
Teladoc Health earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 24 Feb 2027
Latest: Q3 2026
Teladoc Health began rolling out Teladoc One with early launch partners while BetterHelp shifted toward insurance-covered therapy, reaching 3,000+ new therapists in the quarter.
Teladoc Health advanced its Integrated Care offering, implementing Teladoc One, a new comprehensive care model, with early launch partners, and expanding hybrid care and AI-enabled tools. Chronic care enrollment reached 1.344 million, up 15%, even as U.S. Integrated Care members slipped 2% to 100.1 million. At BetterHelp, insurance-covered revenue grew from a small base to $32.1 million as cash-pay users kept declining.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $640.5M * |
| Q1 2025 | $629.4M |
| Q2 2025 | $631.9M |
| Q3 2025 | $626.4M |
| Q4 2025 | $642.3M * |
| Q1 2026 | $613.8M |
| Q2 2026 | $606.9M |
| Q3 2026 | $605.1M |
Data
| Q1 2025 | -$0.53 |
| Q2 2025 | -$0.19 |
| Q3 2025 | -$0.28 |
| Q1 2026 | -$0.36 |
| Q2 2026 | -$0.21 |
| Q3 2026 | -$0.15 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -7.5% |
| Q1 2025 | -19.2% |
| Q2 2025 | -8.6% |
| Q3 2025 | -8.3% |
| Q4 2025 | -5.6% |
| Q1 2026 | -10.1% |
| Q2 2026 | -6.1% |
| Q3 2026 | -4.6% |
Data
| Q4 2024 | $79.8M |
| Q1 2025 | $13.2M |
| Q2 2025 | $90.2M |
| Q3 2025 | $97.0M |
| Q4 2025 | $85.1M |
| Q1 2026 | $7.9M |
| Q2 2026 | $63.7M |
| Q3 2026 | $105.2M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $640.5Md | $629.4M | $631.9M | $626.4M | $642.3Md | $613.8M | $606.9M | $605.1M |
| Operating income | -$48.2Md | -$120.6M | -$54.4M | -$52.0M | -$36.0Md | -$61.8M | -$37.1M | -$28.1M |
| Operating margin | -7.5% | -19.2% | -8.6% | -8.3% | -5.6% | -10.1% | -6.1% | -4.6% |
| Net income | -$48.4Md | -$93.0M | -$32.7M | -$49.5M | -$25.1Md | -$63.8M | -$38.9M | -$26.9M |
| Diluted EPS | — | -$0.53 | -$0.19 | -$0.28 | — | -$0.36 | -$0.21 | -$0.15 |
| Operating cash flow | $85.9Md | $15.9M | $91.4Md | $99.3Md | $87.7Md | $9.5M | $64.7Md | $106.5Md |
| Capital expenditure | $6.1Md | $2.7M | $1.3Md | $2.3Md | $2.6Md | $1.7M | $928.0Kd | $1.2Md |
| Free cash flow | $79.8M | $13.2M | $90.2M | $97.0M | $85.1M | $7.9M | $63.7M | $105.2M |
| R&D expense | $76.8Md | $70.0M | $68.8M | $67.6M | $71.6Md | $67.9M | $62.9M | $65.5M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 29 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 30 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 30 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 26 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 30 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 27 Feb 202510-K for the period ended 31 Dec 2024SEC ↗